Manifaxine
Encyclopedia
Manifaxine is a drug developed by GlaxoSmithKline
through structural modification of radafaxine
, the active metabolite of bupropion
. It acts as a norepinephrine-dopamine reuptake inhibitor
(NDRI). It was researched for treatment of ADHD and obesity
and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom...
through structural modification of radafaxine
Radafaxine
Radafaxine is drug candidate designated GW-353,162 by GlaxoSmithKline, investigated for treatment of restless leg syndrome and as an NDRI antidepressant...
, the active metabolite of bupropion
Bupropion
Bupropion is an atypical antidepressant and smoking cessation aid. The drug is a non-tricyclic antidepressant and differs from most commonly prescribed antidepressants such as SSRIs, as its primary pharmacological action is thought to be norepinephrine-dopamine reuptake inhibition...
. It acts as a norepinephrine-dopamine reuptake inhibitor
Norepinephrine-dopamine reuptake inhibitor
A norepinephrine-dopamine reuptake inhibitor is a drug which acts as a reuptake inhibitor for the neurotransmitters norepinephrine and dopamine by blocking the action of the norepinephrine transporter and the dopamine transporter , respectively...
(NDRI). It was researched for treatment of ADHD and obesity
Obesity
Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems...
and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.